Pharmacists play an important role in providing education and support with adherence to PrEP in populations with a high risk for HIV infection.
Additional support is necessary to ensure that infrastructure development continues and that all pharmacists have the necessary tools to continue to provide immunization services.
Many health care systems use these products to provide similar but cheaper clinical outcomes.
There are several key areas of risk that infusion practices are likely to face at some point, and proactively preparing for these events can help ensure a positive outcome.
Analytics allow for a better understanding of the needs of various patient populations and the barriers they face in accessing care.
Pharmacists as immunizers are vaccine distributors, educators, facilitators, and administrators.
Results of the ACTIV-6 study showed that high dose ivermectin use did not demonstrate a clinical benefit for mild to moderate COVID-19.
Despite demonstrating numerous benefits, semaglutide has also been linked to an increased incidence of diabetic retinopathy, which was initially reported in the SUSTAIN-6 trial.
Many of patients with hepatitis that pharmacists encounter have viral hepatitis, which can be easily remembered as the ABCs of hepatitis.
Vaccination provides an opportunity to prevent and treat herpes simplex virus infection.
Organizations should focus on improving employee well-being and reducing workplace stressors.
Approval of a novel antibody-drug conjugate ushers in new second-line option.
Your pharmacy’s bottom line needs a smarter pricing system to keep up with a tech-smart customer. But when should you make the move?
Novel therapeutics under investigation include CAR T-cell therapies, antibody-drug conjugates, and bispecific antibodies, as well as other unique drugs.
Pandemic allows technicians to shine and be increasingly viewed as key to streamlining workflow.
The objective of this study is to evaluate the use of low-dose pioglitazone, without relying on high doses of insulin, by enhancing sensitivity as a suitable, cost-effective strategy compared to larger insulin doses in patients with limited access to care.
Tucatinib is indicated to treat adults with advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer who have already received at least 1 anti-HER2-based regimen in the metastatic setting.
Studies suggest novel immunotherapy may have efficacy as monotherapy and in combination with an anti-PD-1 immune checkpoint inhibitor.
Digitizing hub processes can create an efficient and effective tech-driven patient access strategy speeding access to lifesaving therapies.
Despite demonstrating numerous benefits, semaglutide has also been linked to an increased incidence of diabetic retinopathy, which was initially reported in the SUSTAIN-6 trial.
Outpatient treatment is primarily based on patient-specific factors, whereas oseltamivir remains the therapy of choice for inpatient settings.
Additional support is necessary to ensure that infrastructure development continues and that all pharmacists have the necessary tools to continue to provide immunization services.
Closing out their discussion on marginal zone lymphoma, the panel considers which future treatment strategies are most promising.
Beyond the benefits to the pharmacist profession, granting provider status to pharmacists addresses the larger societal problem of growing physician shortages.
Experts in gynecologic oncology provide insight on available patient assistance programs to help lower costs of PARP inhibitors for the treatment of ovarian cancer, and how pharmacists can aid in obtaining this information.
There is not yet an FDA-approved treatment available for monkeypox, but existing antiviral agents have been found to be effective in vitro and in animal studies.
Lack of acknowledgement or rewards in high-pressure pharmacy environments can lead to mental health issues.
Pharmacists can play a key role in providing education and guidance to patients with glaucoma.